Durham R&D Tax Credit Benefits for Businesses

R&D Tax Credits for Durham, North Carolina Businesses

Durham, North Carolina, thrives in industries such as healthcare, education, technology, manufacturing, and retail. Top companies in the city include Duke University Health System, a leading healthcare provider; Duke University, a major educational institution; IBM, a significant technology employer; GlaxoSmithKline, a key player in the manufacturing sector; and The Streets at Southpoint, a prominent retail complex. The R&D Tax Credit can provide tax savings for these industries by incentivizing innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 6255 Towncenter Drive, Clemmons, North Carolina is less than 90 miles away from Durham and provides R&D tax credit consulting and advisory services to Durham and the surrounding areas such as: Greensboro, Winston-Salem, Fayetteville, Cary and High Point.

If you have any questions or need further assistance, please call or email our local North Carolina Partner on (984) 480-4601.
Feel free to book a quick teleconference with one of our North Carolina R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Durham, North Carolina Patent of the Year – 2024/2025

Nirvana Sciences Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking advancement in medical imaging. Their invention, detailed in U.S. Patent No. 11904026, titled ‘Metallohydroporphyrins for photoacoustic imaging’, introduces novel contrast agents that enhance the clarity and depth of photoacoustic imaging, a technique that combines light and sound to visualize tissues.

This innovation employs copper- and manganese-based chlorins and bacteriochlorins as contrast agents. These compounds absorb light and emit sound waves, allowing for sharper and deeper imaging of biological tissues. The result is a significant improvement in the ability to detect and monitor diseases such as cancer and cardiovascular conditions.

Unlike traditional imaging methods, photoacoustic imaging with these metallohydroporphyrins offers enhanced resolution and penetration depth. This means clinicians can obtain more detailed images of organs and tissues without invasive procedures. The technology also supports multiplex imaging, enabling simultaneous visualization of multiple targets within the body.

By integrating these advanced contrast agents into photoacoustic imaging, Nirvana Sciences Inc. is paving the way for more accurate diagnostics and personalized treatment plans. This patent not only represents a leap forward in imaging technology but also holds promise for improving patient outcomes across various medical fields.